Tocagen Inc. and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction.
Galderma has announced positive results from OSCAR, a phase IV trial, a multicenter, randomized, investigator-blinded, vehicle-controlled, intra-individual comparison study (right/left...
Galderma Laboratories announced that the FDA approved antibiotic-free Epiduo Forte (adapalene and benzoyl peroxide) Gel, 0.3%/2.5%, for the once-daily, topical...
The relief of smooth muscle spasm in conditions such as irritable bowel syndrome, painful diverticular disease of the colon and primary dysmenorrhoea.